Metabolite elucidation of the Hsp90 inhibitor SNX-2112 using ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS)

Pharmacokinetics, Metabolism, and Excretion of the Antiviral Drug Arbidol in Humans

(2013) Pan Deng et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-κB and disruption of mitochondria-dependent pathways

(2013) Rui Wang et al.   CHEMICO-BIOLOGICAL INTERACTIONS

Human Cytochrome P450 1A1 Structure and Utility in Understanding Drug and Xenobiotic Metabolism

(2013) Agnes A. Walsh et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients

(2012) Cen Xie et al.   BRITISH JOURNAL OF PHARMACOLOGY

Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds

(2012) A. Palmeira et al.   CURRENT MEDICINAL CHEMISTRY

Structure and Ligand-based Design of P-glycoprotein Inhibitors: A Historical Perspective

(2012) Andreia Palmeira et al.   CURRENT PHARMACEUTICAL DESIGN

Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures andin silicomodeling

(2012) Dong Dong et al.   DRUG METABOLISM REVIEWS

Integrated quantitative and qualitative workflow forin vivobioanalytical support in drug discovery using hybrid Q-TOF-MS

(2012) Asoka Ranasinghe et al.   Bioanalysis

Recent advances in metabolite identification and quantitative bioanalysis by LC–Q-TOF MS

(2012) Cen Xie et al.   Bioanalysis

SNX-2112, a Novel Hsp90 Inhibitor, Induces G2/M Cell Cycle Arrest and Apoptosis in MCF-7 Cells

(2011) Shao-Xiang WANG et al.   BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY

SNX-2112, an Hsp90 inhibitor, induces apoptosis and autophagy via degradation of Hsp90 client proteins in human melanoma A-375 cells

(2011) Kai-Sheng Liu et al.   CANCER LETTERS

Antitumor Activity of SNX-2112, a Synthetic Heat Shock Protein-90 Inhibitor, in MET-Amplified Tumor Cells with or without Resistance to Selective MET Inhibition

(2011) T. Bachleitner-Hofmann et al.   CLINICAL CANCER RESEARCH

A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas

(2011) A. Rajan et al.   CLINICAL CANCER RESEARCH

Identification of Amiodarone Metabolites in Human Bile by Ultraperformance Liquid Chromatography/Quadrupole Time-of-Flight Mass Spectrometry

(2011) P. Deng et al.   DRUG METABOLISM AND DISPOSITION

It is time for a paradigm shift in drug discovery bioanalysis: from SRM to HRMS

(2011) Ragu Ramanathan et al.   JOURNAL OF MASS SPECTROMETRY

Anti-tumor activity of the HSP90 inhibitor SNX-2112 in pediatric cancer cell lines

(2011) Danielle C. Chinn et al.   PEDIATRIC BLOOD & CANCER

Microsomal cytochrome P450-mediated metabolism of hypaconitine, an active and highly toxic constituent derived from Aconitum species

(2011) Ling Ye et al.   TOXICOLOGY LETTERS

Preclinical pharmacokinetic analysis of SNX-2112, a novel Hsp90 inhibitor, in rats

(2010) Q.Q. Zhai et al.   BIOMEDICINE & PHARMACOTHERAPY

Glucuronidation of Dihydrotestosterone and trans-Androsterone by Recombinant UDP-Glucuronosyltransferase (UGT) 1A4: Evidence for Multiple UGT1A4 Aglycone Binding Sites

(2009) J. Zhou et al.   DRUG METABOLISM AND DISPOSITION

Discovery of Novel 2-Aminobenzamide Inhibitors of Heat Shock Protein 90 as Potent, Selective and Orally Active Antitumor Agents

(2009) Kenneth H. Huang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Quantitation of small molecules using high-resolution accurate mass spectrometers - a different approach for analysis of biological samples

(2009) Nanyan Rena Zhang et al.   RAPID COMMUNICATIONS IN MASS SPECTROMETRY

Generic dealkylation: a tool for increasing the hit-rate of metabolite rationalization, and automatic customization of mass defect filters

(2009) Russell J. Mortishire-Smith et al.   RAPID COMMUNICATIONS IN MASS SPECTROMETRY

Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90

(2008) Thomas E. Barta et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK

(2008) Y. Okawa et al.   BLOOD

SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase Dependent Cancers

(2008) S. Chandarlapaty et al.   CLINICAL CANCER RESEARCH